Full Press Release Details
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024.
Details of the presentations can be found below.
H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Location: The Nasdaq Headquarters, New York City
Presenter: Mark Erlander, CEO
Format: Fireside Chat
Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Presenter: Mark Erlander, CEO
Format: Fireside Chat
Interested parties can register for and access the live webcasts for these conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replays will be available after the conclusion of the respective presentations.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
Chief Financial Officer